Guinea-Bissau

Reimbursed Care Access

Guinea-Bissau is a party to the UN drug control conventions that require national controls on psychotropic and narcotic substances; as a practical matter classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca) have no authorised medical or reimbursed use and are controlled under national law consistent with those treaties [https://treaties.un.org/Pages/showDetails.aspx?objid=08000002800079ad|UN Treaty — Convention on Psychotropic Substances]. Ketamine is listed on the WHO Model List of Essential Medicines for use as an anaesthetic and therefore is the only compound among those requested with clear, routine medical use worldwide — this implies likely availability for anaesthesia in Guinea‑Bissau’s health system, but there is no evidence of a publicly reimbursed, psychedelic‑therapy program or of esketamine (Spravato) being authorized or reimbursed locally. Key practical consequences: most psychedelic compounds are accessible only in research settings (or illicit markets) in Guinea‑Bissau; ketamine is used medically as an anaesthetic but not as a routinely reimbursed mental‑health therapy product. [https://medlistapp.paho.org/en/list/11|WHO Model List of Essential Medicines — ketamine].